eli lilly glp-1 mounjaro endowment launches weight-loss drug in India, beats Novo Nordisk to major market Eli Lilly's New $299 Month-Long

The medicine is evolving quickly, having already expanded to include oral treatments with the first-ever FDA approval for a GLP-1 pill for weight loss for Wegovy at the end of 2025

This dual mechanism appears to produce even greater effects on blood sugar and body weight than GLP-1-only medications

GLP-1 agonist shortage will last until end of 2024, government warns

Abstract Along the obesity pandemic, the prevalence of non-alcoholic fatty liver disease (NAFLD), often regarded as the hepatic manifestation of the metabolic syndrome, increases worldwide representing now the prevalent liver disease in western countries

The hospital pharmacies segment led the market in 2024, owing to their role in dispensing specialty and high-cost drugs under medical supervision, especially for newly initiated treatments and titration monitoring